Targeting Indoleamine 2,3-Dioxygenase in Cancer Models Using the Novel Small Molecule Inhibitor NTRC 3883-0

Indoleamine 2,3-dioxygenase (IDO1) is a key regulator of immune suppression by catalyzing the oxidation of L-tryptophan. IDO1 expression has been related to poor prognosis in several cancers and to resistance to checkpoint immunotherapies. We describe the characterization of a novel small molecule I...

Descripción completa

Detalles Bibliográficos
Autores principales: Grobben, Yvonne, de Man, Jos, van Doornmalen, Antoon M., Muller, Michelle, Willemsen-Seegers, Nicole, Vu-Pham, Diep, Mulder, Winfried R., Prinsen, Martine B. W., de Wit, Joeri, Sterrenburg, Jan Gerard, van Cauter, Freek, den Ouden, Judith E., van Altena, Anne M., Massuger, Leon F., Uitdehaag, Joost C. M., Buijsman, Rogier C., Zaman, Guido J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876453/
https://www.ncbi.nlm.nih.gov/pubmed/33584686
http://dx.doi.org/10.3389/fimmu.2020.609490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876453/
https://www.ncbi.nlm.nih.gov/pubmed/33584686
http://dx.doi.org/10.3389/fimmu.2020.609490

Ejemplares similares